

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(10) International Publication Number

WO 2014/141171 A1

(43) International Publication Date
18 September 2014 (18.09.2014)

WIPO | PCT

(51) International Patent Classification:
C07D 413/04 (2006.01) *A61P 37/00* (2006.01)
A61K 31/4433 (2006.01)

(21) International Application Number:
PCT/IB2014/059794

(22) International Filing Date:
14 March 2014 (14.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13159482.2 15 March 2013 (15.03.2013) EP

(71) Applicant: ACTELION PHARMACEUTICALS LTD
[CH/CH]; Gewerbestrasse 16, CH-4123 Allschwil (CH).

(72) Inventors: BOLLI, Martin; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). LE-SCOP, Cyrille; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). NAYLER, Oliver; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). STEINER, Beat; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(74) Agent: GSCHWEND, Thomas; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: PYRIDIN-4-YL DERIVATIVES



Formula (I)

(57) **Abstract:** The invention relates to compounds of the Formula (I), Formula (I) wherein R¹ and R² are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.



Published:

— *with international search report (Art. 21(3))*

Pyridin-4-yl Derivatives

5 Field of the Invention

The present invention relates to S1P₁/EDG1 receptor agonists of Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, 10 pharmaceutical compositions containing a compound of the Formula (I), and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.

15 Description of the Invention

The human immune system is designed to defend the body against foreign micro-organisms and substances that cause infection or disease. Complex regulatory mechanisms ensure that the immune response is targeted against the intruding substance or organism and not against the host. In some cases, these control mechanisms are 20 unregulated and autoimmune responses can develop. A consequence of the uncontrolled inflammatory response is severe organ, cell, tissue or joint damage. With current treatment, the whole immune system is usually suppressed and the body's ability to react to infections is also severely compromised. Typical drugs in this class include azathioprine, chlorambucil, cyclophosphamide, cyclosporin, or methotrexate. Corticosteroids which 25 reduce inflammation and suppress the immune response, may cause side effects when used in long term treatment. Nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce pain and inflammation, however, they exhibit considerable side effects. Alternative treatments include agents that activate or block cytokine signaling.

Orally active compounds with immunomodulating properties, without compromising 30 immune responses and with reduced side effects would significantly improve current treatments of uncontrolled inflammatory diseases.

In the field of organ transplantation the host immune response must be suppressed to prevent organ rejection. Organ transplant recipients can experience some rejection even when they are taking immunosuppressive drugs. Rejection occurs most frequently in the 35 first few weeks after transplantation, but rejection episodes can also happen months or

even years after transplantation. Combinations of up to three or four medications are commonly used to give maximum protection against rejection while minimizing side effects. Current standard drugs used to treat the rejection of transplanted organs interfere with discrete intracellular pathways in the activation of T-type or B-type white blood cells.

5 Examples of such drugs are cyclosporin, daclizumab, basiliximab, everolimus, or FK506, which interfere with cytokine release or signaling; azathioprine or leflunomide, which inhibit nucleotide synthesis; or 15-deoxyspergualin, an inhibitor of leukocyte differentiation.

The beneficial effects of broad immunosuppressive therapies relate to their effects; however, the generalized immunosuppression which these drugs produce diminishes the 10 immune system's defense against infection and malignancies. Furthermore, standard immunosuppressive drugs are often used at high dosages and can cause or accelerate organ damage.

Detailed Description of the Invention


15 The present invention provides novel compounds of Formula (I) that are agonists for the G protein-coupled receptor S1P₁/EDG1 and have a powerful and long-lasting immunomodulating effect which is achieved by reducing the number of circulating and infiltrating T- and B-lymphocytes, without affecting their maturation, memory, or expansion.

20 The reduction of circulating T- / B-lymphocytes as a result of S1P₁/EDG1 receptor agonism, possibly in combination with the observed improvement of endothelial cell layer function associated with S1P₁/EDG1 receptor activation, makes such compounds useful to treat uncontrolled inflammatory diseases and to improve vascular functionality. Prior art document WO 2008/029371 (document **D1**) discloses compounds that act as S1P₁/EDG1 receptor agonists and show an immunomodulating effect as described above. On the other hand, several reports suggest that activation of the S1P₃ receptor is associated with vaso- and bronchoconstriction (e.g. Salomone et al. *Brit. J. Pharmacol.* **153** (2008) 140-147; Murakami et al. *Mol. Pharmacol.* **77** (2010) 704-713; Lucke et al. *Cellular Physiology and Biochemistry* **26** (2010) 87-96), blood pressure increase (e.g. Fryer et al. *PLOS One* **7** (2012) e52985), heart rate reduction (e.g. Hamada et. al. *J. Med. Chem.* **53** (2010) 3154-3168) and pulmonary epithelial leakage (e.g. Gon et al. *PNAS* **102** (2005) 9270-9275). Selectivity against the S1P₃ receptor is therefore deemed an advantage of a given S1P₁ receptor agonist (e.g. Hale et al. *Bioorg. Med. Chem. Lett.* **14** (2004) 3501-3505).


30

35 Unexpectedly, it has been found that the compounds of the present invention have a reduced activity on the S1P₃ receptor when compared to closest analogs disclosed in

document **D1**. This becomes evident from the data listed in Table 1 and Table 2. The compound of Example 1 of the present invention, for instance, shows an EC₅₀ of 9950 nM for the S1P₃ receptor while its closests analog in document **D1** (Example 57 of **D1**) shows an EC₅₀ value of 1540 nM. Similarly, the compound of Example 2 is clearly less potent on 5 S1P₃ receptor when compared to its closest analog disclosed in document **D1** (Example 101 of **D1**). Also, Example 5 of the present invention is significantly less potent on S1P₃ receptor when compared to its analog of document **D1** (S-enantiomer of the racemate of Example 22 of **D1**), and the same is true for the compounds of Examples 7 and 8 and their corresponding analogs in document **D1** (Example 204 and Example 233, respectively, of 10 **D1**).

Table 1:

Example	R ¹	EC ₅₀ [nM]	
		S1P ₁	S1P ₃
1	ethyl	2.1	9950
2	n-propyl	0.7	1120
3	isopropyl	0.3	3940
4	n-butyl	1.8	700
5	isobutyl	0.2	757
6	isopentyl	5.1	2600
7	pent-3-yl	0.1	1340
8	cyclopentyl	0.1	736

Table 2:

5

Closest Analog in D1	R^1	$\text{EC}_{50} [\text{nM}]$	
		S1P_1	S1P_3
to Example 1 (Example 57 of D1)	ethyl	0.3	1540
to Example 2 (Example 101 of D1)	n-propyl	0.4	310
to Example 5 (S-entiomeric of Example 22 of D1)	isobutyl	0.1	33
to Example 7 (Example 204 of D1)	pent-3-yl	0.2	44
to Example 8 (Example 233 of D1)	cyclopentyl	0.2	47


Taken together, the data presented in Table 1 and 2 clearly demonstrate that with respect to reduced activity on the S1P_3 receptor, the pyridine derivatives of the present invention are superior to the corresponding 2-methyl-pyridine analogs disclosed in document D1, 10 regardless of the nature of substituent R^1 of the compounds of Formula (I) of the present invention.

The compounds of the present invention can be utilized alone or in combination with standard drugs inhibiting T-cell activation, to provide a new immunomodulating therapy with 15 a reduced propensity for infections when compared to standard immunosuppressive

therapy. Furthermore, the compounds of the present invention can be used in combination with reduced dosages of traditional immunosuppressant therapies, to provide on the one hand effective immunomodulating activity, while on the other hand reducing end organ damage associated with higher doses of standard immunosuppressive drugs. The 5 observation of improved endothelial cell layer function associated with S1P₁/EDG1 receptor activation provides additional benefits of compounds to improve vascular function.

The nucleotide sequence and the amino acid sequence for the human S1P₁/EDG1 and S1P₃/EDG3 receptors are known in the art and are published in e.g.: Hla, T., and Maciag, 10 T., *J. Biol. Chem.* **265** (1990), 9308-9313; WO 91/15583 published 17 October 1991; WO 99/46277 published 16 September 1999; Yamaguchi F., Tokuda M., Hatase O., Brenner S., *Biochem. Biophys. Res. Commun.* **227** (1996), 608-614; An S., Bleu T., Huang W., Hallmark O.G., Coughlin S.R., Goetzl E.J., *FEBS Lett.* **417** (1997), 279-282. The potency and efficacy of the compounds of Formula (I) 15 are assessed using a GTP γ S assay to determine EC₅₀ values and by measuring the circulating lymphocytes in the rat after oral administration, respectively (see in experimental part).

i) In a first embodiment, the invention relates to a compound of the Formula (I),



wherein

25 **R**¹ represents C₂₋₅-alkyl, preferably wherein the carbon atom which is attached to the pyridine ring carries at least one hydrogen atom, or cyclopentyl; and

R² represents -OCH₂-CH(OH)-CH₂-NHCO-CH₂OH.

ii) Another embodiment of the invention relates to a compound according to embodiment i), wherein \mathbf{R}^1 represents ethyl, n-propyl, isopropyl, n-butyl, isobutyl, isopentyl, pent-3-yl, or cyclopentyl.

5 iii) Another embodiment of the invention relates to a compound according to embodiment i), wherein \mathbf{R}^1 represents n-propyl, isopropyl, isobutyl, or cyclopentyl.

iv) Another embodiment of the invention relates a compound according to embodiment i), wherein \mathbf{R}^1 represents cyclopentyl.

10 v) Another embodiment of the invention relates to a compound according to any one of embodiments i) to iv), wherein the stereocenter of the \mathbf{R}^2 group $-\text{OCH}_2\text{-CH(OH)-CH}_2\text{-NHCO-CH}_2\text{OH}$ is in the S-configuration.

15 The term **C₂₋₅-alkyl** means saturated, branched or straight chain alkyl groups with two to five carbon atoms.

The compounds of Formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. The compounds of Formula (I) 20 may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.

Where the plural form is used for compounds, salts, pharmaceutical compositions, 25 diseases and the like, this is intended to mean also a single compound, salt, or the like.

Any reference hereinbefore or hereinafter to a compound of Formula (I) is to be understood as referring also to salts, especially pharmaceutically acceptable salts, of a compound of Formula (I), as appropriate and expedient.

30 The term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound. For reference see 35 for example 'Handbook of Pharmaceutical Salts. Properties, Selection and Use.', P.

Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008 and 'Pharmaceutical Salts and Co-crystals', Johan Wouters and Luc Quéré (Eds.), RSC Publishing, 2012.

The present invention also includes isotopically labelled, especially ^2H (deuterium) labelled compounds of Formula (I), which compounds are identical to the compounds of Formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially ^2H (deuterium) labelled compounds of Formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope ^2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased *in vivo* half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of Formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of Formula (I) are not isotopically labelled at all. Isotopically labelled compounds of Formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.

Examples of pyridine compounds according to Formula (I) are selected from:

(S)-N-(3-(2-ethyl-4-(5-(2-ethylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-propylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-isopropylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-butylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-isobutylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-isopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-(pentan-3-yl)-pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide; and

(S)-N-(3-(2-ethyl-4-(5-(2-cyclopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide.

The compounds of Formula (I) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such as especially oral) or parenteral (including topical application or inhalation) administration, and 5 are suitable for decreasing the number of circulating lymphocytes and for the prevention and/or treatment of diseases or disorders associated with an activated immune system.

The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, *The Science and 10 Practice of Pharmacy*, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of Formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and, if 15 desired, usual pharmaceutical adjuvants.

The pharmaceutical compositions comprising a compound of Formula (I) are useful for the prevention and/or treatment of diseases or disorders associated with an activated immune system.

20 Such diseases or disorders associated with an activated immune system and to be prevented/treated with the compounds of Formula (I) are for example selected from the group consisting of rejection of transplanted organs, tissue or cells; graft-versus-host diseases brought about by transplantation; autoimmune syndromes including rheumatoid 25 arthritis; systemic lupus erythematosus; antiphospholipid syndrome; Hashimoto's thyroiditis; lymphocytic thyroiditis; multiple sclerosis; myasthenia gravis; type I diabetes; uveitis; episcleritis; scleritis; Kawasaki's disease, uveo-retinitis; posterior uveitis; uveitis associated with Behcet's disease; uveomeningitis syndrome; allergic encephalomyelitis; chronic allograft vasculopathy; post-infectious autoimmune diseases including rheumatic 30 fever and post-infectious glomerulonephritis; inflammatory and hyperproliferative skin diseases; psoriasis; psoriatic arthritis; atopic dermatitis; myopathy; myositis; osteomyelitis; contact dermatitis; eczematous dermatitis; seborrhoeic dermatitis; lichen planus; pemphigus; bullous pemphigoid; epidermolysis bullosa; urticaria; angioedema; vasculitis; erythema; cutaneous eosinophilia; acne; scleroderma; alopecia areata; keratoconjunctivitis; 35 vernal conjunctivitis; keratitis; herpetic keratitis; dystrophia epithelialis cornea; corneal leukoma; ocular pemphigus; Mooren's ulcer; ulcerative keratitis; scleritis; Graves'

ophthalmopathy; Vogt-Koyanagi-Harada syndrome; sarcoidosis; pollen allergies; reversible obstructive airway disease; bronchial asthma; allergic asthma; intrinsic asthma; extrinsic asthma; dust asthma; chronic or inveterate asthma; late asthma and airway hyper-responsiveness; bronchiolitis; bronchitis; endometriosis; orchitis; gastric ulcers; ischemic bowel diseases; inflammatory bowel diseases; necrotizing enterocolitis; intestinal lesions associated with thermal burns; coeliac disease; proctitis; eosinophilic gastroenteritis; mastocytosis; Crohn's disease; ulcerative colitis; vascular damage caused by ischemic diseases and thrombosis; atherosclerosis; fatty heart; myocarditis; cardiac infarction; aortitis syndrome; cachexia due to viral disease; vascular thrombosis; migraine; rhinitis; eczema; interstitial nephritis; IgA-induced nephropathy; Goodpasture's syndrome; hemolytic-uremic syndrome; diabetic nephropathy; glomerulosclerosis; glomerulonephritis; tubulointerstitial nephritis; interstitial cystitis; multiple myositis; Guillain-Barré syndrome; Meniere's disease; polyneuritis; multiple neuritis; myelitis; mononeuritis; radiculopathy; hyperthyroidism; Basedow's disease; thyrotoxicosis; pure red cell aplasia; aplastic anemia; hypoplastic anemia; idiopathic thrombocytopenic purpura; autoimmune hemolytic anemia; autoimmune thrombocytopenia; agranulocytosis; pernicious anemia; megaloblastic anemia; anerythroplasia; osteoporosis; fibroid lung; idiopathic interstitial pneumonia; dermatomyositis; leukoderma vulgaris; ichthyosis vulgaris; photoallergic sensitivity; cutaneous T cell lymphoma; polyarteritis nodosa; Huntington's chorea; Sydenham's chorea; myocarditis; myocarditis; scleroderma; Wegener's granuloma; Sjogren's syndrome; adiposis; eosinophilic fascitis; lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis; male pattern alopecia or alopecia senilis; muscular dystrophy; pyoderma; Sezary's syndrome; hypophysitis; chronic adrenal insufficiency; Addison's disease; ischemia-reperfusion injury of organs which occurs upon preservation; endotoxin shock; pseudomembranous colitis; colitis caused by drug or radiation; ischemic acute renal insufficiency; chronic renal insufficiency; lung cancer; malignancy of lymphoid origin; acute or chronic lymphocytic leukemias; lymphoma; pulmonary emphysema; cataracta; siderosis; retinitis pigmentosa; senile macular degeneration; vitreal scarring; corneal alkali burn; dermatitis erythema; ballous dermatitis; cement dermatitis; gingivitis; periodontitis; sepsis; pancreatitis; peripheral artery disease; carcinogenesis; solid cancer tumors; metastasis of carcinoma; hypobaropathy; autoimmune hepatitis; primary biliary cirrhosis; sclerosing cholangitis; partial liver resection; acute liver necrosis; cirrhosis; alcoholic cirrhosis; hepatic failure; fulminant hepatic failure; late-onset hepatic failure; and "acute-on-chronic" liver failure.

Preferred diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, 5 multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, and uveoretinitis; atopic diseases such as rhinitis, conjunctivitis, and atopic dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; and solid cancers and tumor metastasis.

10

Particularly preferred diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from the group consisting of rejection of transplanted organs selected from kidney, liver, heart and lung; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes selected from 15 rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; and atopic dermatitis. Very preferably the diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from multiple sclerosis and psoriasis.

20

The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of Formula (I).

25

Furthermore, compounds of the Formula (I) are also useful, in combination with one or several immunomodulating agents, for the prevention and/or treatment of the diseases and disorders mentioned herein. According to a preferred embodiment of the invention, said agents are selected from the group consisting of immunosuppressants, corticosteroids, NSAID's, cytotoxic drugs, adhesion molecule inhibitors, cytokines, cytokine inhibitors, cytokine receptor antagonists and recombinant cytokine receptors.

30

The present invention also relates to the use of a compound of Formula (I) for the preparation of a pharmaceutical composition, optionally for use in combination with one or several immunomodulating agents, for the prevention or treatment of the diseases and disorders mentioned herein.


35

The compounds of Formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.

5


Compounds of the Formula (I) of the present invention can be prepared according to the general sequence of reactions outlined below. Only a few of the synthetic possibilities leading to compounds of Formula (I) are described.

10 Compounds of Formula (I) are prepared by reacting a compound of Structure 1 in a solvent such as toluene, pyridine, DMF, THF, dioxane, DME, etc. at rt or elevated temperatures in the presence or absence of auxiliaries such as acids (e.g. TFA, acetic acid, HCl, etc.), bases (e.g. NaH, NaOAc, Na₂CO₃, K₂CO₃, NEt₃, etc.), tetraalkylammonium salts, or water removing agents (e.g. oxalyl chloride, a carboxylic acid anhydride, POCl₃, PCl₅, P₄O₁₀, 15 molecular sieves, Burgess reagent, etc.) (Lit.: e.g. A. R. Gangloff, J. Litvak, E. J. Shelton, D. Sperandio, V. R. Wang, K. D. Rice, *Tetrahedron Lett.* **42** (2001), 1441-1443; T. Suzuki, K. Iwaoka, N. Imanishi, Y. Nagakura, K. Miyata, H. Nakahara, M. Ohta, T. Mase, *Chem. Pharm. Bull.* **47** (1999), 120-122; R. F. Poulain, A. L. Tartar, B. P. Déprez, *Tetrahedron Lett.* **42** (2001), 1495-1498; R. M. Srivastava, F. J. S. Oliveira, D. S. Machado, R. M. Souto- 20 Maior, *Synthetic Commun.* **29** (1999), 1437-1450; E. O. John, J. M. Shreeve, *Inorganic Chemistry* **27** (1988), 3100-3104; B. Kaboudin, K. Navaee, *Heterocycles* **60** (2003), 2287-2292).




25 Compounds of Structure 1 may be prepared by reacting a compound of Structure 2 with a compound of Structure 3 in a solvent such as DMF, THF, DCM, etc. in the presence of one or more coupling agents such as TBTU, DCC, EDC, HBTU, CDI, etc. and in the presence or absence of a base such as NEt₃, DIPEA, NaH, K₂CO₃, etc. (Lit.: e.g. A. Hamze, J.-F. Hernandez, P. Fulcrand, J. Martinez, *J. Org. Chem.* **68** (2003), 7316-7321; and the 30 literature cited above).

12




Structure 2




Structure 3

Compounds of Structure 3 may be prepared by reacting a compound of Structure 4, with 5 hydroxylamine or one of its salts in a solvent such as MeOH, EtOH, pyridine, etc. in the presence or absence of a base such as Na_2CO_3 , K_2CO_3 , potassium tert.butylate, NEt_3 , etc. (Lit.: e.g. E. Meyer, A. C. Joussef, H. Gallardo, *Synthesis* **2003**, 899-905, WO 2004/035538 (Merck & Co., Inc., USA)).



10

Structure 4



Structure 5

Compounds of Structure 2 may be prepared by reacting 2-chloro-isonicotinic acid or a suitable ester derivative thereof (Structure 5, wherein R represents e.g. methyl, ethyl, 15 isopropyl, etc.) with dialkyl-Zn, an alkyl-Zn or cycloalkyl-Zn halogen reagent under Negishi conditions (Lit.: e.g. H. Matsushita, E. Negishi, *J. Org. Chem.* **47** (1982), 4161-4165), with an appropriate alkyl or cycloalkyl Grignard reagent for instance in the presence of $\text{Fe}(\text{acac})_3$ in a solvent such as THF, dioxane, DMF, NMP, etc., or combinations thereof, at temperatures ranging from -78 to 25°C under Fürstner conditions (Lit.: e.g. A. Fürstner, A. 20 Leitner, M. Mendez, H. Krause, *J. Am. Chem. Soc.* **124** (2002), 13856-13863; A. Fürstner, A. Leitner, *Angew. Chem.* **114** (2002), 632-635) or with 1-alkenyl or cycloalken-1-yl-boron derivative (Lit.: e.g. F. Kerins, D. F. O'Shea, *J. Org. Chem.* **67** (2002), 4968-4971) under Suzuki coupling conditions (Lit.: e.g. H. Doucet, *Eur. J. Org. Chem.* **2008**, 2013-2030). In 25 case 1-alkenyl boron derivatives are used to introduce the carbon framework of R^1 , a subsequent hydrogenation step is required to establish the desired alkyl or cycloalkyl group. Finally, in case a pyridine-4-carboxylic acid ester has been employed in the steps described above, ester hydrolysis under basic or acid reaction conditions furnishes the desired compound of Structure 2.

Whenever the compounds of Formula (I) are obtained in the form of mixtures of stereoisomers such as especially enantiomers, the stereoisomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Daicel ChiralPak AD-H (5 μ m) 5 column, a Daicel ChiralCel OD-H (5 μ m) column, a Daicel ChiralCel OD (10 μ m) column, a Daicel ChiralPak IA (5 μ m) column, a Daicel ChiralPak IB (5 μ m) column, a Daicel ChiralPak IC (5 μ m) column, or a (R,R)-Whelk-01 (5 μ m) column. Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of a base like NEt₃ and/or diethylamine or of an acid like TFA) and eluent B (heptane).

10

Experimental Part

The following examples illustrate the invention but do not at all limit the scope thereof.

15 All temperatures are stated in °C. Compounds are characterized by **¹H-NMR** (300 MHz) or **¹³C-NMR** (75 MHz) (Varian Oxford; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet, p = pentuplet, hex = hexet, hept = heptet, m = multiplet, br = broad, coupling constants are given in Hz); by **LC-MS** (Finnigan Navigator with HP 1100 Binary Pump and DAD, column: 4.6x50 mm, Zorbax SB-AQ, 5 μ m, 20 120 Å, gradient: 5-95% MeCN in water, 1 min, with 0.04% TFA, flow: 4.5 mL/min, t_R is given in min; by **TLC** (TLC-plates from Merck, Silica gel 60 F₂₅₄); or by melting point. Compounds are purified by prep. HPLC (column: X-terra RP18, 50x19 mm, 5 μ m, gradient: 10-95% MeCN in water containing 0.5 % of formic acid) or by MPLC (Labomatic MD-80-100 pump, Linear UVIS-201 detector, column: 350x18 mm, Labogel-RP-18-5s-100, 25 gradient: 10% MeOH in water to 100% MeOH).

Abbreviations (as used herein):

aq.	aqueous
BSA	bovine serum albumin
30 Burgess reagent	methoxycarbonylsulfamoyl triethylammonium hydroxide
CC	column chromatography
CDI	carbonyl diimidazole
DCC	N,N'-dicyclohexyl carbodiimide
DCM	dichloromethane
35 DEAD	diethyl-diazodicarboxylate

	DIPEA	Hüning's base, diethylisopropylamine
	DME	1,2-dimethoxyethane
	DMF	dimethylformamide
	DMSO	dimethylsulfoxide
5	dppf	1,1'-bis(diphenylphosphino)ferrocene
	EA	ethyl acetate
	EDC	N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide
	Et	ethyl
	EtOH	ethanol
10	Fe(acac) ₃	iron(III) acetylacetone-complex
	h	hour(s)
	HBTU	O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
	HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
15	HOEt	1-hydroxy-benzotriazole
	HPLC	high performance liquid chromatography
	LC-HRMS	liquid chromatography – high resolution mass spectrometry
	LC-MS	liquid chromatography – mass spectrometry
	Lit.	literature
20	Me	methyl
	MeCN	acetonitrile
	MeOH	methanol
	min	minute(s)
	MPLC	medium pressure liquid chromatography
25	NaOAc	sodium acetate
	NEt ₃	triethylamine
	NMP	1-methyl-2-pyrrolidone
	org.	organic
	PPh ₃	triphenylphosphine
30	prep.	preparative
	quant.	quantitative
	rt	room temperature
	sat.	saturated
	S1P	sphingosine 1-phosphate
35	TBTU	2-(1H-benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate

tert.	tertiary
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin layer chromatography
5 t_R	retention time

Preparation of Intermediates

10 N-((S)-3-[2-Ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide

a) To an ice-cold solution of H_2SO_4 (150 mL) in water (250 mL), 2-ethyl-6-methylaniline (15.0 g, 111 mmol) is added. The solution is treated with ice (150 g) before a solution of $NaNO_2$ (10.7 g, 155 mmol) in water (150 mL) and ice (50 g) is added dropwise. The mixture is stirred at 0°C for 1 h. 50% aq. H_2SO_4 (200 mL) is added and stirring is continued at rt for 18 h. The mixture is extracted with DCM, the org. extracts are dried over $MgSO_4$ and evaporated. The crude product is purified by CC on silica gel eluting with heptane:EA 9:1 to give 2-ethyl-6-methyl-phenol (8.6 g, 57%) as a crimson oil; LC-MS: t_R = 0.89 min; 1H NMR ($CDCl_3$): δ 7.03-6.95 (m, 2H), 6.80 (t, J = 7.6 Hz, 1H), 4.60 (s, 1H), 2.64 (q, J = 7.6 Hz, 2H), 2.25 (s, 3H), 1.24 (t, J = 7.6 Hz, 3H).

b) A solution of 2-ethyl-6-methyl phenol (200 g, 1.47 mol) and hexamethylene tetraamine (206 g, 1.47 mol) in acetic acid (1600 mL) and water (264 mL) is heated to reflux. The condensate is removed using a Dean-Stark apparatus until about 1200 mL of condensate are collected. The reaction mixture is cooled to rt and water (1000 mL) is added. The thick suspension is filtered and the collected solid is dried at 60°C under vacuum (10 mbar) to give 3-ethyl-4-hydroxy-5-methyl-benzaldehyde (191 g, 79%) as an orange solid; LC-MS: t_R = 0.86 min, $[M+1+CH_3CN]^+$ = 206.27; 1H NMR ($CDCl_3$): δ 9.84 (s, 1 H), 7.59 (s, 1 H), 7.57 (s, 1 H), 4.64 (s br, 1 H), 2.71 (q, J = 7.5 Hz, 2 H), 2.34 (s, 3 H), 1.30 (t, J = 7.5 Hz, 3 H).

c) A solution of 3-ethyl-4-hydroxy-5-methyl-benzaldehyde (5.32 g, 32.4 mmol) and hydroxylamine hydrochloride (3.38 g, 48.6 mmol) in NMP (35 mL) is stirred for 3 h at 80°C under microwave irradiation (300 W, continuous cooling, A. K. Chakraborti, G. Kaur, *Tetrahedron* **55** (1999) 13265-13268). The mixture is diluted with water and extracted twice with diethyl ether. The org. extracts are washed with 2 N aq. HCl, sat. aq. $NaHCO_3$ solution and brine. The org. extracts are combined, dried over Na_2SO_4 , filtered and concentrated. The crude product is purified by CC on silica gel eluting with heptane:EA 3:2 to give 3-

ethyl-4-hydroxy-5-methyl-benzonitrile as a pale yellow solid (4.80 g, 92%); LC-MS: t_R = 0.90 min; ^1H NMR (CDCl_3): δ 1.24 (t, J = 7.6 Hz, 3 H), 2.26 (s, 3 H), 2.63 (q, J = 7.6 Hz, 2 H), 5.19 (s, 1 H), 7.30 (s, 2 H).

5 d) To a solution of 3-ethyl-4-hydroxy-5-methyl-benzonitrile (5.06 g, 31.4 mmol) in THF (80 mL), PPh_3 (9.06 g, 34.5 mmol) and (R)-glycidol (2.29 mL, 34.5 mmol) are added. The mixture is cooled to 0°C before DEAD in toluene (15.8 mL, 34.5 mmol) is added. The mixture is stirred for 18 h while warming up to rt. The solvent is evaporated and the crude product is purified by CC on silica gel eluting with heptane:EA 7:3 to give (S)-3-ethyl-5-methyl-4-(oxiran-2-ylmethoxy)benzonitrile (5.85 g, 86%) as a yellow oil; LC-MS: t_R = 0.96 min, $[\text{M}+42]^+ = 259.08$; ^1H NMR (CDCl_3): δ 7.38 (s, 1 H), 7.35 (s, 1 H), 4.12-4.19 (m, 1 H), 3.73-3.80 (m, 1 H), 3.36-3.42 (m, 1 H), 2.90-2.96 (m, 1 H), 2.68-2.77 (m, 3 H), 2.34 (s, 3 H), 1.26 (t, J = 7.6 Hz, 3 H).

10 15 e) The above (S)-3-ethyl-5-methyl-4-(oxiran-2-ylmethoxy)benzonitrile (5.85 g, 26.9 mmol) is dissolved in 7 N NH_3 in methanol (250 mL) and the solution is stirred at 65°C for 18 h. The solvent is evaporated to give crude (S)-4-(3-amino-2-hydroxypropoxy)-3-ethyl-5-methylbenzonitrile (6.23 g, quant.) as a yellow oil; LC-MS: t_R = 0.66 min, $[\text{M}+1]^+ = 235.11$; ^1H NMR ($\text{D}_6\text{-DMSO}$): δ 7.54 (s, 2 H), 4.96 (s br, 1 H), 3.77-3.83 (m, 1 H), 3.68-3.77 (m, 2 H), 2.59-2.75 (m, 4 H), 2.28 (s, 3 H), 1.58 (s br, 2 H), 1.17 (t, J = 7.5 Hz, 3 H).

20 25 f) To a solution (S)-4-(3-amino-2-hydroxypropoxy)-3-ethyl-5-methylbenzonitrile (6.23 g, 26.6 mmol), glycolic acid (2.43 g, 31.9 mmol), HOEt (4.31 g, 31.9 mmol), and EDC hydrochloride (6.12 g, 31.9 mmol) are added. The mixture is stirred at rt for 18 h before it is diluted with sat. aq. NaHCO_3 and extracted twice with EA. The combined org. extracts are dried over MgSO_4 , filtered and concentrated. The crude product is purified by CC with DCM containing 8% of methanol to give (S)-N-[3-(4-cyano-2-ethyl-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide (7.03 g, 90%) as a yellow oil; LC-MS: t_R = 0.74 min, $[\text{M}+1]^+ = 293.10$; ^1H NMR (CDCl_3): δ 1.25 (t, J = 7.5 Hz, 3 H), 2.32 (s, 3 H), 2.69 (q, J = 7.5 Hz, 2 H), 3.48-3.56 (m, 3 H), 3.70-3.90 (m, 3 H), 4.19 (s, br, 3 H), 7.06 (m, 1 H), 7.36 (s, 1 H), 7.38 (s, 1 H).

30 35 g) To a solution of (S)-N-[3-(4-cyano-2-ethyl-6-methyl-phenoxy)-2-hydroxy-propyl]-2-hydroxy-acetamide (19.6 g, 67 mmol) in methanol (500 mL) is added hydroxylamine hydrochloride (9.32 g, 134 mmol) and NaHCO_3 (11.3 g, 134 mmol). The resulting suspension is stirred at 65°C for 18 h. The mixture is filtered and the filtrate is

concentrated. The residue is dissolved in water (20 mL) and EA (300 mL). The aq. phase is separated and extracted three times with EA. The combined org. extracts are dried over MgSO₄, filtered, concentrated and dried to give the title compound as white solid (18.9 g, 87%); LC-MS: t_R = 0.51 min, [M+1]⁺ = 326.13; ¹H NMR (D₆-DMSO): δ 1.17 (t, J 7.4Hz, 3 H), 2.24 (s, 3H), 2.62 (q, J 7.4Hz, 2 H), 3.23 (m, 1 H), 3.43 (m, 1 H), 3.67 (m, 2 H), 3.83 (s, 2 H), 3.93 (m, 1 H), 5.27 (s br, 1 H), 5.58 (s br, 1 H), 5.70 (s, 2 H), 7.34 (s, 1 H), 7.36 (s, 1 H), 7.67 (m, 1 H), 9.46 (s br, 1H).

2-Ethylisonicotinic acid

10 The title compound is prepared as hydrochloride salt in analogy to 2-(pentan-3-yl)isonicotinic acid; LC-MS: t_R = 0.22 min, [M+1]⁺ = 152.13; ¹H NMR (CD₃OD): δ 8.68 (d, J = 5.4 Hz, 1 H), 7.99 (s, 1 H), 7.91 (dd, J₁ = 5.3 Hz, J₂ = 1.3 Hz, 1 H), 2.98 (q, J = 7.6 Hz, 2 H), 1.37 (t, J = 7.6 Hz, 3 H).

15 **2-Propylisonicotinic acid**

The title compound is prepared as hydrochloride salt in analogy to 2-(pentan-3-yl)isonicotinic acid; LC-MS: t_R = 0.20 min, [M+1]⁺ = 166.10. Methyl 2-propylisonicotinate: LC-MS: t_R = 0.43 min, [M+1]⁺ = 180.33; ¹H NMR (CDCl₃): δ 8.67 (d, J = 5.0 Hz, 1 H), 7.70 (s, 1 H), 7.64 (dd, J₁ = 5.1 Hz, J₂ = 1.5 Hz, 1 H), 3.95 (s, 3 H), 2.82-2.87 (m, 2 H), 1.73-1.84 (m, 2 H), 0.97 (t, J = 7.4 Hz, 3 H).

2-Isopropylisonicotinic acid

The title compound is prepared as hydrochloride salt in analogy to 2-(pentan-3-yl)isonicotinic acid; LC-MS: t_R = 0.18 min, [M+1]⁺ = 166.09; ¹H NMR (D₇-DMF): δ 8.49 (d, J = 4.9 Hz, 1 H), 7.82 (s, 1 H), 7.74 (dd, J₁ = 4.9 Hz, J₂ = 1.1 Hz, 1 H), 2.99-3.08 (m, 1 H), 1.25 (d, J = 6.9 Hz, 6 H).

2-Butylisonicotinic acid

30 The title compound is prepared as hydrochloride salt in analogy to 2-(pentan-3-yl)isonicotinic acid; LC-MS: t_R = 0.32 min, [M+1]⁺ = 180.37; ¹H NMR (D₇-DMF): δ 8.98 (d, J = 5.8 Hz, 1 H), 8.38 (s, 1 H), 8.30 (dd, J₁ = 5.8 Hz, J₂ = 1.4 Hz, 1 H), 3.28-3.34 (m, 2 H), 1.83-1.93 (m, 2 H), 1.36-1.48 (m, 2 H), 0.95 (t, J = 7.3 Hz, 3 H).

2-Isobutylisonicotinic acid

35 a) To a solution of 2-chloroisonicotinic acid (5.00 g, 31.7 mmol) in toluene is added N,N-dimethylformamide di-tert. butylacetal (17.9 g, 79.3 mmol). The mixture is stirred at 90°C

for 20 h. The mixture is concentrated, filtered and the filtrate is diluted with EA and washed with water, dried over MgSO_4 , filtered and concentrated. The crude product is purified by CC on silica gel eluting heptane:EA 5:1 to give tert. butyl 2-chloroisonicotinate (2.23 g, 33%) as a colourless oil; LC-MS: $t_{\text{R}} = 0.98$ min, $[\text{M}+1+\text{CH}_3\text{CN}]^+ = 255.31$.

5

b) Under argon, to a solution of tert. butyl 2-chloroisonicotinate (2.23 g, 10.4 mmol) in THF (50 mL) is added $\text{Fe}(\text{acac})_3$ (405 mg, 1.15 mmol) followed by NMP (1.45 g, 14.6 mmol). The mixture is cooled to -75°C before isobutylmagnesium chloride (8 mL of a 2 M solution in THF) is added. The mixture is stirred at -75°C for 1 h, then at rt for 1 h. The reaction is quenched by adding water (100 mL) and the mixture is extracted with EA. The org. extract is dried over MgSO_4 , filtered and concentrated. The crude product is purified by CC on silica gel eluting with heptane:EA 4:1 to give tert. butyl 2-isobutylisonicotinate (630 mg, 26%) as a pale yellow oil; LC-MS: $t_{\text{R}} = 0.82$ min, $[\text{M}+1]^+ = 236.39$.

10 c) A mixture of tert. butyl 2-isobutylisonicotinate (630 mg, 2.68 mmol) in 25% aq. HCl (10 mL) is stirred at 60°C for 20 h. The mixture is concentrated and dried under high vacuum to give the title compound (640 mg, quant.) as hydrochloride salt; LC-MS: $t_{\text{R}} = 0.47$ min, $[\text{M}+1]^+ = 180.09$; ^1H NMR (CD_3OD): δ 8.88 (d, $J = 5.9$ Hz, 1 H), 8.34 (s, 1 H), 8.29 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, 1 H), 3.00 (d, $J = 7.4$ Hz, 2 H), 2.14-2.24 (m, 1 H), 1.03 (d, $J = 6.6$ Hz, 6 H).

15 20

2-Isopentylisonicotinic acid

The title compound is prepared in analogy to 2-isobutylisonicotinic acid; tert. butyl 2-isopentylisonicotinate: LC-MS: $t_{\text{R}} = 0.88$ min, $[\text{M}+1]^+ = 250.40$; ^1H NMR (CDCl_3): δ 8.64 (d, $J = 5.0$ Hz, 1 H), 7.66 (s, 1 H), 7.60 (d, $J = 5.0$ Hz, 1 H), 2.82-2.91 (m, 2 H), 1.57-1.70 (m, 12 H), 0.97 (d, $J = 5.6$ Hz, 6 H). Title compound: LC-MS: $t_{\text{R}} = 0.58$ min, $[\text{M}+1]^+ = 194.30$.

2-(Pentan-3-yl)isonicotinic acid

To a solution of methyl 2-chloroisonicotinate (4.59 g, 26.7 mmol) in dry dioxane (120 mL), 30 $\text{Pd}(\text{dppf})$ (2.18 g, 2.67 mmol) is added under argon. To this red-brown suspension 3-pentyl zink (11.6 g, 53.5 mmol, 107 mL of a 0.5 M solution in THF) is added and the mixture is stirred at 100°C for 18 h. The black solution is cooled to rt, diluted with EA (200 mL) and washed with water (100 mL) and 2 N aq. HCl. The washings are extracted four times with DCM (4x100 mL). The combined org. extracts are dried over MgSO_4 , filtered and concentrated. The crude product is purified by MPLC on silica gel eluting with a gradient of EA in heptane to give methyl 2-(pentan-3-yl)isonicotinate (1.15 g, 21%) as brownish oil

35

containing a few percent of methyl 2-(pentan-2-yl)isonicotinate; LC-MS: $t_R = 0.62$ min; $[M+1]^+ = 208.30$. This material is dissolved in THF (30 mL) and 25% aq. HCl (25 mL) and the mixture is stirred at 70°C for 18 h before it is concentrated and dried to give the title compound (467 mg, 37%) as a beige solid; LC-MS: $t_R = 0.35$ min, $[M+1]^+ = 194.28$; ^1H NMR (CD_3OD): δ 8.74 (d, $J = 5.2$ Hz, 1 H), 7.97 (s, 1 H), 7.96 (d, $J = 6.0$ Hz, 1 H), 2.74-2.84 (m, 1 H), 1.71-1.91 (m, 4 H), 0.83 (t, $J = 7.4$ Hz, 6 H).


2-Cyclopentylisonicotinic acid

The title compound is prepared in analogy to 2-(pentan-3-yl)isonicotinic acid; LC-MS: $t_R = 0.42$ min, $[M+1]^+ = 192.28$; ^1H NMR (CDCl_3): δ 8.93 (s, 1 H), 8.17-8.37 (m, 2 H), 3.77-3.91 (m, 1 H), 2.36-2.48 (m, 2 H), 1.80-1.94 (m, 4 H), 1.70-1.79 (m, 2 H).

Examples

15 Example 1

(S)-N-(3-(2-Ethyl-4-(5-(2-ethylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide




20 To a solution of N-((S)-3-[2-ethyl-4-(N-hydroxycarbamimidoyl)-6-methyl-phenoxy]-2-hydroxy-propyl)-2-hydroxy-acetamide (290 mg, 1.60 mmol) in DMF (15 mL), EDC HCl (307 mg, 1.60 mmol) and HOEt (216 mg, 1.60 mmol) is added. The mixture is stirred at rt for 20 min before 2-ethyl-isonicotinic acid (347 mg, 1.07 mmol) is added. Stirring is continued at rt for 1 h. The mixture is diluted with ethyl acetate (50 mL) and washed twice with sat. aq. NaHCO_3 solution (2x10 mL) and brine (1x10 mL). The org. extract is dried over MgSO_4 , filtered and concentrated. The remaining residue is dissolved in dioxane (8 mL) and the mixture is stirred at 120°C for 1 h. The mixture is concentrated and the crude product is purified by prep. HPLC (Waters XBridge 10 μm , 75x30 mm ID, eluting with a gradient of acetonitrile in water containing 0.5% of formic acid) to give the title compound (114 mg) as pale beige solid; LC-MS: $t_R = 0.63$ min, $[M+1]^+ = 441.23$; ^1H NMR (CDCl_3): δ 8.77 (d, $J = 5.0$ Hz, 1 H), 7.94 (s, 1 H), 7.84-7.88 (m, 3 H), 7.20 (t, $J = 5.5$ Hz, 1 H), 4.18-4.25 (m, 3 H), 3.90 (dd, $J_1 = 9.5$ Hz, $J_2 = 4.5$ Hz, 1 H), 3.85 (dd, $J_1 = 9.5$ Hz, $J_2 = 6.3$ Hz, 1 H), 3.79 (ddd,

$J_1 = 14.1$ Hz, $J_2 = 6.5$ Hz, $J_3 = 3.3$ Hz, 1 H), 3.72 (s br, 1 H), 3.49-3.58 (m, 1 H), 2.99 (q, $J = 7.6$ Hz, 2 H), 2.75 (q, $J = 7.5$ Hz, 2 H), 2.38 (s, 3 H), 1.41 (t, $J = 7.6$ Hz, 3 H), 1.32 (t, $J = 7.5$ Hz, 3 H).

5 Example 2


(S)-N-(3-(2-ethyl-4-(5-(2-propylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide



Prepared in analogy to Example 1. Beige solid; LC-MS: $t_R = 0.68$ min, $[M+1]^+ = 455.22$; ^1H NMR (CDCl_3): δ 8.77 (d, $J = 5.1$ Hz, 1 H), 7.93 (s, 1 H), 7.84-7.89 (m, 3 H), 7.20 (t br, $J = 5.8$ Hz, 1 H), 4.18-4.25 (m, 3 H), 3.90 (dd, $J_1 = 9.6$ Hz, $J_2 = 4.7$ Hz, 1 H), 3.85 (dd, $J_1 = 9.5$ Hz, $J_2 = 6.1$ Hz, 1 H), 3.79 (ddd, $J_1 = 14.1$ Hz, $J_2 = 6.5$ Hz, $J_3 = 3.0$ Hz, 1 H), 3.49-3.58 (m, 1 H), 2.90-2.96 (m, 2 H), 2.75 (q, $J = 7.5$ Hz, 2 H), 2.39 (s, 3 H), 1.81-1.91 (m, 2 H), 1.32 (t, $J = 7.5$ Hz, 3 H), 1.04 (t, $J = 7.3$ Hz, 3 H); ^{13}C NMR (CDCl_3): δ 173.8, 173.7, 168.9, 164.0, 157.4, 150.2, 137.7, 131.7, 131.5, 128.3, 126.6, 122.3, 120.5, 118.7, 74.2, 70.0, 62.1, 42.3, 40.3, 23.0, 22.8, 16.5, 14.8, 13.9.

Example 3

(S)-N-(3-(2-Ethyl-4-(5-(2-isopropylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide




Prepared in analogy to Example 1. Beige solid; LC-MS: $t_R = 0.71$ min, $[M+1]^+ = 455.20$; ^1H NMR (CDCl_3): δ 8.75 (d, $J = 5.1$ Hz, 1 H), 7.93 (s, 1 H), 7.81-7.86 (m, 3 H), 7.37 (t, $J = 5.8$ Hz, 1 H), 4.16-4.24 (m, 3 H), 3.82-3.92 (m, 2 H), 3.78 (ddd, $J_1 = 14.0$ Hz, $J_2 = 6.5$ Hz, $J_3 = 3.1$ Hz, 1 H), 3.48-3.57 (m, 1 H), 3.22 (hept, $J = 7.0$ Hz, 1 H), 2.73 (q, $J = 7.5$ Hz, 2 H), 2.37 (s, 3 H), 1.40 (d, $J = 6.9$ Hz, 6 H), 1.30 (t, $J = 7.5$ Hz, 3 H); ^{13}C NMR (CDCl_3): δ 174.0,

173.4, 169.04, 168.99, 157.4, 150.2, 137.7, 131.70, 131.67, 128.4, 126.7, 122.4, 118.9, 118.6, 74.1, 70.1, 62.2, 42.3, 36.5, 22.9, 22.5, 16.5, 14.8.

Example 4


5 (S)-N-(3-(2-ethyl-4-(5-(2-butylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide



Prepared in analogy to Example 1. Beige solid; LC-MS: $t_R = 0.75$ min, $[M+1]^+ = 469.19$; 1H NMR ($CDCl_3$): δ 8.77 (d, $J = 5.1$ Hz, 1 H), 7.93 (s, 1 H), 7.82-7.89 (m, 3 H), 7.24 (t br, $J = 5.7$ Hz, 1 H), 4.18-4.25 (m, 3 H), 3.90 (dd, $J_1 = 9.6$ Hz, $J_2 = 4.7$ Hz, 1 H), 3.85 (dd, $J_1 = 9.5$ Hz, $J_2 = 6.1$ Hz, 1 H), 3.79 (ddd, $J_1 = 14.2$ Hz, $J_2 = 6.7$ Hz, $J_3 = 3.3$ Hz, 1 H), 3.49-3.57 (m, 1 H), 3.15 (s br, 2 H), 2.91-2.98 (m, 2 H), 2.74 (q, $J = 7.5$ Hz, 2 H), 2.38 (s, 3 H), 1.76-1.85 (m, 2 H), 1.40-1.50 (m, 2 H), 1.31 (t, $J = 7.5$ Hz, 3 H), 0.99 (t, $J = 7.3$ Hz, 3 H); ^{13}C NMR ($CDCl_3$): δ 174.0, 173.2, 169.0, 164.3, 157.4, 150.3, 137.7, 131.7, 131.5, 128.4, 126.7, 122.4, 120.5, 118.7, 74.1, 70.2, 62.2, 42.3, 38.1, 31.9, 22.9, 22.5, 16.5, 14.8, 13.9.

Example 5

20 (S)-N-(3-(2-Ethyl-4-(5-(2-isobutylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide




Prepared in analogy to Example 1. Beige wax; LC-MS: $t_R = 0.73$ min, $[M+1]^+ = 469.21$; 1H NMR ($CDCl_3$): δ 8.79 (d, $J = 5.1$ Hz, 1 H), 7.85-7.91 (m, 4 H), 7.14 (t, $J = 5.6$ Hz, 1 H), 4.17-4.26 (m, 3 H), 3.76-3.94 (m, 3 H), 3.61 (s br, 1 H), 3.49-3.58 (m, 1 H), 3.28 (s br, 1 H), 2.82 (d, $J = 7.2$ Hz, 2 H), 2.75 (q, $J = 7.5$ Hz, 2 H), 2.39 (s, 3 H), 2.14-2.28 (m, 1 H), 1.32 (t, $J = 7.5$ Hz, 3 H), 1.00 (d, $J = 6.6$ Hz, 6 H); ^{13}C NMR ($CDCl_3$): δ 173.9, 173.5, 169.0, 163.4, 157.4, 150.3, 137.7, 131.7, 131.4, 128.4, 126.7, 122.4, 121.2, 118.7, 74.2, 70.1, 62.2, 47.5,

42.3, 29.4, 22.9, 22.4, 16.5, 14.8; LC-HRMS: $t_R = 1.78$ min, $[M+H]/z = 469.2451$, found = 469.2446.

Example 6

5 (S)-N-(3-(2-ethyl-4-(5-(2-isopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide




Prepared in analogy to Example 1. White solid; LC-MS: $t_R = 0.92$ min, $[M+1]^+ = 483.18$; 1H NMR ($CDCl_3$): δ 8.79 (d, $J = 5.1$ Hz, 1 H), 7.95 (s, 1 H), 7.86-7.90 (m, 3 H), 7.12 (t, $J = 5.8$ Hz, 1 H), 4.17-4.26 (m, 3 H), 3.91 (dd, $J_1 = 9.5$ Hz, $J_2 = 4.8$ Hz, 1 H), 3.77-3.88 (m, 2 H), 3.53 (m, 1 H), 2.93-2.99 (m, 2 H), 2.76 (q, $J = 7.5$ Hz, 2 H), 2.40 (s, 3 H), 1.83-1.88 (m, 2 H), 1.66-1.76 (m, 1 H), 1.33 (t, $J = 7.5$ Hz, 3 H), 1.01 (d, $J = 6.2$ Hz, 6 H); ^{13}C NMR ($CDCl_3$): δ 173.9, 173.4, 169.0, 164.5, 157.5, 150.3, 137.8, 131.7, 131.6, 128.4, 126.7, 122.4, 120.5, 118.7, 74.1, 70.2, 62.2, 46.4, 42.3, 36.4, 28.0, 22.9, 22.5, 16.5, 14.8.

Example 7

(S)-N-(3-(2-ethyl-4-(5-(2-(pentan-3-yl)-pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide

20




Prepared in analogy to Example 1. Beige wax; LC-MS: $t_R = 0.80$ min, $[M+1]^+ = 483.27$; 1H NMR ($CDCl_3$): δ 8.80 (d, $J = 5.1$ Hz, 1 H), 7.81-7.90 (m, 4 H), 7.45 (t, $J = 5.8$ Hz, 1 H), 4.57 (s br, 2 H), 4.16-4.25 (m, 3 H), 3.82-3.92 (m, 2 H), 3.78 (ddd, $J_1 = 14.0$ Hz, $J_2 = 6.5$ Hz, $J_3 = 3.1$ Hz, 1 H), 3.48-3.57 (m, 1 H), 2.68-2.78 (m, 3 H), 2.37 (s, 3 H), 1.74-1.87 (m, 4 H), 1.30 (t, $J = 7.5$ Hz, 3 H), 0.83 (t, $J = 7.4$ Hz, 6 H); ^{13}C NMR ($CDCl_3$): δ 174.1, 173.4, 169.0,

167.2, 157.4, 150.4, 137.7, 131.7, 131.3, 128.4, 126.7, 122.5, 120.5, 118.8, 74.1, 70.1, 62.2, 51.6, 42.3, 28.2, 22.9, 16.5, 14.8, 12.1; LC-HRMS: t_R = 1.93 min, [M+H]/z = 483.2607, found = 483.2601.

5 **Example 8**

(S)-N-(3-(2-ethyl-4-(5-(2-cyclopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide



10 Prepared in analogy to Example 1. White solid; LC-MS: t_R = 0.78 min, [M+1]⁺ = 481.06; ¹H NMR ($CDCl_3$): δ 8.78 (d, J = 5.1 Hz, 1 H), 7.96 (s, 1 H), 7.83-7.88 (m, 3 H), 7.25-7.32 (m, 1 H), 4.17-4.25 (m, 3 H), 3.90 (dd, J_1 = 9.5 Hz, J_2 = 4.5 Hz, 1 H), 3.85 (dd, J_1 = 9.5 Hz, J_2 = 6.0 Hz, 1 H), 3.79 (ddd, J_1 = 14.3 Hz, J_2 = 6.8 Hz, J_3 = 3.3 Hz, 1 H), 3.49-3.58 (m, 1 H), 3.45 (s br, 2 H), 3.29-3.39 (m, 1 H), 2.74 (q, J = 7.5 Hz, 2 H), 2.38 (s, 3 H), 2.13-2.27 (m, 2 H), 1.71-1.97 (m, 6 H), 1.31 (t, J = 7.5 Hz, 3 H); ¹³C NMR ($CDCl_3$): δ 174.1, 173.1, 169.0, 167.5, 157.4, 150.2, 137.7, 131.7, 131.5, 128.4, 126.7, 122.4, 119.5, 118.7, 74.1, 70.2, 62.2, 48.0, 42.3, 33.6, 25.9, 22.9, 16.5, 14.8; LC-HRMS: t_R = 1.90 min, [M+H]/z = 481.2451, found = 481.2450.

20

Example 9

GTP γ S assay to determine EC₅₀ values



GTP γ S binding assays are performed in 96 well microtiter plates (Nunc, 442587) in a final volume of 200 μ l, using membrane preparations of CHO cells expressing recombinant 25 human S1P₁ receptor or human S1P₃ receptor. Assay conditions are 20 mM HEPES (Fluka, 54461), 100 mM NaCl (Fluka, 71378), 5 mM MgCl₂ (Fluka, 63064), 0.1% BSA (Calbiochem, 126609), 1 μ M GDP (Sigma, G-7127), 2.5% DMSO (Fluka, 41644), 50 pM ³⁵S-GTP γ S (Amersham Biosciences, SJ1320). The pH is 7.4. Test compounds are dissolved and diluted in 100% DMSO and pre-incubated at room temperature for 30 min in 30 150 μ l of the above assay buffer, in the absence of ³⁵S-GTP γ S. After addition of 50 μ l of ³⁵S-GTP γ S, the assay is incubated for 1 h at rt. The assay is terminated by transfer of the

reaction mixture to a Multiscreen plate (Millipore, MAHFC1H60) using a cell harvester from Packard Biosciences, and the plates are washed with ice-cold 10 mM Na₂HPO₄/NaH₂PO₄ (70%/30%), dried, sealed at the bottom and, after addition of 25 μ l MicroScint20 (Packard Biosciences, order# 6013621), sealed on the top. Membrane-bound ³⁵S-GTP γ S is measured with a TopCount from Packard Biosciences.

EC₅₀ is the concentration of agonist inducing 50 % of the maximal specific ³⁵S-GTP γ S binding. Specific binding is determined by subtracting non-specific binding from maximal binding. Maximal binding is the amount of cpm bound to the Multiscreen plate in the presence of 10 μ M of S1P. Non-specific binding is the amount of binding in the absence of an agonist in the assay.

Agonistic activities (EC₅₀ values) of all exemplified compounds have been measured and are in the range of 0.1 to 5.1 nM with an average of 1.3 nM on S1P₁ receptor. EC₅₀ values on S1P₃ receptor are in the range of 700 and 9950 with an average of 2641 nM. Agonistic activities are displayed in Table 3.

Table 3:

Compound of Example	R ¹	R ²	EC ₅₀ [nM]	
			S1P ₁	S1P ₃
1	ethyl		2.1	9950
2	n-propyl		0.7	1120

25					
3	isopropyl		0.3	3940	
4	n-butyl		1.8	700	
5	isobutyl		0.2	757	
6	isopentyl		5.1	2600	
7	pent-3-yl		0.1	1340	
8	cyclopentyl		0.1	736	

Example 10

Assessment of *In vivo* Efficacy

5 The efficacy of the compounds of Formula (I) is assessed by measuring the circulating lymphocytes after oral administration of 3 to 30 mg/kg of a compound of Formula (I) to normotensive male Wistar rats. The animals are housed in climate-controlled conditions with a 12 h-light/dark cycle, and have free access to normal rat chow and drinking water. Blood is collected before and 3, 6 and 24 h after drug administration. Full blood is 10 subjected to hematology using Advia Hematology system (Bayer Diagnostics, Zürich, Switzerland).

All data are presented as mean \pm SEM. Statistical analyses are performed by analysis of variance (ANOVA) using Statistica (StatSoft) and the Student-Newman-Keuls procedure for 15 multiple comparisons. The null hypothesis is rejected when $p < 0.05$.


As an example, Table 4 shows the effect on lymphocyte counts 6 h after oral administration of 10 mg/kg of a compound of the present invention to normotensive male Wistar rats as compared to a group of animals treated with vehicle only. Lymphocyte counts 6 h after oral administration have been measured for 2 out of 8 exemplified compounds and are in the range of -71% to -73% with an average of -72%.

Table 4:

Compound of Example	Lymphocyte counts
7	-71%
8	-73%

Claims

1. A compound of Formula (I),



5

Formula (I)

wherein

R¹ represents C₂₋₅-alkyl or cyclopentyl; and

10

R² represents -OCH₂-CH(OH)-CH₂-NHCO-CH₂OH;

or a salt thereof.

15

2. A compound according to claim 1, wherein **R¹** represents ethyl, n-propyl, isopropyl, n-butyl, isobutyl, isopentyl, pent-3-yl, or cyclopentyl, or a salt thereof.

3. A compound according to claim 1, wherein **R¹** represents n-propyl, isopropyl, isobutyl, or cyclopentyl, or a salt thereof.

20

4. A compound according to claim 1, wherein **R¹** represents cyclopentyl, or a salt thereof.

5. A compound according to any one of claims 1 to 4, wherein the stereocenter of the **R²** group -OCH₂-CH(OH)-CH₂-NHCO-CH₂OH is in the S-configuration, or a salt thereof.

25

6. A compound according to claim 1 selected from the group consisting of:

(S)-N-(3-(2-ethyl-4-(5-(2-ethylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-propylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methyl-phenoxy)-2-

30

hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-isopropylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-butylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

5 (S)-N-(3-(2-ethyl-4-(5-(2-isobutylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-isopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide;

(S)-N-(3-(2-ethyl-4-(5-(2-(pentan-3-yl)-pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide; and

10 (S)-N-(3-(2-ethyl-4-(5-(2-cyclopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide; or a salt of such compounds.

15 7. A compound according to claim 1 which is (S)-N-(3-(2-ethyl-4-(5-(2-cyclopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide or a salt thereof.

8. A pharmaceutical composition comprising a compound according to any one of claims 1
20 to 7, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 8, for use as a
25 medicament.

10. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of diseases or disorders associated with an activated immune system.

30 11. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of diseases or disorders selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis,

psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, and uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, and atopic dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; and solid cancers and tumor metastasis.

5

12. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of diseases or disorders selected from the group consisting of rejection of transplanted organs selected from kidney, liver, heart and lung; graft-versus-host diseases brought about by stem cell transplantation; 10 autoimmune syndromes selected from rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; and atopic dermatitis.
13. Use of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the 15 prevention or treatment of diseases or disorders associated with an activated immune system.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2014/059794

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D413/04 A61K31/4433 A61P37/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 2008/029371 A1 (ACTELION PHARMACEUTICALS LTD [CH]; BOLLI MARTIN [CH]; LEHMANN DAVID [C]) 13 March 2008 (2008-03-13) cited in the application claims 1-4,20-24; examples 22,56,57,99,101,121,123,203,204,232,233</p> <p>-----</p> <p style="text-align: center;">-/-</p>	1-13

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
13 May 2014	10/06/2014
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Hass, Christian

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2014/059794

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HALE J J ET AL: "Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 14, no. 13, 5 July 2004 (2004-07-05), pages 3501-3505, XP002718181, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2004.04.070 cited in the application tables 1,2,3 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/IB2014/059794

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008029371	A1	13-03-2008	AR 062683 A1 26-11-2008
			AU 2007292993 A1 13-03-2008
			BR PI0716171 A2 17-09-2013
			CA 2661105 A1 13-03-2008
			CL 25932007 A1 13-06-2008
			CN 101511827 A 19-08-2009
			DK 2069336 T3 25-02-2013
			EP 2069336 A1 17-06-2009
			ES 2400533 T3 10-04-2013
			HK 1133654 A1 14-09-2012
			HR P20130181 T1 31-03-2013
			IL 197393 A 30-09-2013
			JP 5253401 B2 31-07-2013
			JP 2010502695 A 28-01-2010
			KR 20090050102 A 19-05-2009
			MA 30718 B1 01-09-2009
			MY 149853 A 31-10-2013
			NZ 576060 A 25-11-2011
			PT 2069336 E 07-03-2013
			RU 2009112538 A 20-10-2010
			SI 2069336 T1 29-03-2013
			TW 200817357 A 16-04-2008
			US 2010063108 A1 11-03-2010
			WO 2008029371 A1 13-03-2008